Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
Authors
Keywords
-
Journal
EBioMedicine
Volume 83, Issue -, Pages 104217
Publisher
Elsevier BV
Online
2022-08-12
DOI
10.1016/j.ebiom.2022.104217
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
- (2022) Peter B. Gilbert et al. SCIENCE
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1
- (2021) Jungsoon Lee et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
- (2021) Shilong Yang et al. LANCET INFECTIOUS DISEASES
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays
- (2021) Kevin R. Bewley et al. Nature Protocols
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
- (2021) Nicole Doria-Rose et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
- (2021) Stefania Dispinseri et al. Nature Communications
- SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
- (2021) Jeroen Pollet et al. Human Vaccines & Immunotherapeutics
- Antibodies and Vaccines Target RBD of SARS-CoV-2
- (2021) Long Min et al. Frontiers in Molecular Biosciences
- Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate
- (2021) Wen-Hsiang Chen et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
- (2021) Amy Flaxman et al. LANCET
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- (2021) Ann R. Falsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Vaccines: Where Are We Now?
- (2021) Katie L. Flanagan et al. Journal of Allergy and Clinical Immunology-In Practice
- Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
- (2021) Shuo Feng et al. NATURE MEDICINE
- Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate
- (2021) Wen-Hsiang Chen et al. PROTEIN EXPRESSION AND PURIFICATION
- Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
- (2021) Chris Davis et al. PLoS Pathogens
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia
- (2020) Qun Li et al. NEW ENGLAND JOURNAL OF MEDICINE
- Signals of Th2 immune response from COVID-19 patients requiring intensive care
- (2020) Luca Roncati et al. ANNALS OF HEMATOLOGY
- A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
- (2020) Jingyun Yang et al. NATURE
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Expansion of SARS-CoV-2–Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
- (2020) Renata Varnaitė et al. JOURNAL OF IMMUNOLOGY
- Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
- (2020) Tsun-Yung Kuo et al. Scientific Reports
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started